A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetics and pharmacodynamics of
LY2963016 and US-approved Lantus®. The study involves four single injections; two doses of
LY2963016 and two doses of US-approved Lantus®. The study will have 4 periods. In each
period, a single injection will be administered before undergoing a euglycemic clamp that
lasts for 24 hours. There will be at least a 7 day washout between each period. Side effects
will be documented. Study participation is expected to last up to 14 weeks.